PMID- 19219303 OWN - NLM STAT- MEDLINE DCOM- 20091008 LR - 20190606 IS - 1414-431X (Electronic) IS - 0100-879X (Linking) VI - 42 IP - 1 DP - 2009 Jan TI - Antidipsogenic effects of central adenosine-5'-triphosphate. PG - 105-13 LID - S0100-879X2009000100015 [pii] AB - Besides other physiological functions, adenosine-5'-triphosphate (ATP) is also a neurotransmitter that acts on purinergic receptors. In spite of the presence of purinergic receptors in forebrain areas involved with fluid-electrolyte balance, the effect of ATP on water intake has not been investigated. Therefore, we studied the effects of intracerebroventricular (icv) injections of ATP (100, 200 and 300 nmol/microL) alone or combined with DPCPX or PPADS (P1 and P2 purinergic antagonists, respectively, 25 nmol/microL) on water intake induced by water deprivation. In addition, the effect of icv ATP was also tested on water intake induced by intragastric load of 12% NaCl (2 mL/rat), acute treatment with the diuretic/natriuretic furosemide (20 mg/kg), icv angiotensin II (50 ng/microL) or icv carbachol (a cholinergic agonist, 4 nmol/microL), on sodium depletion-induced 1.8% NaCl intake, and on food intake induced by food deprivation. Male Holtzman rats (280-320 g, N = 7-11) had cannulas implanted into the lateral ventricle. Icv ATP (300 nmol/microL) reduced water intake induced by water deprivation (13.1 +/- 1.9 vs saline: 19.0 +/- 1.4 mL/2 h; P < 0.05), an effect blocked by pre-treatment with PPADS, but not DPCPX. Icv ATP also reduced water intake induced by NaCl intragastric load (5.6 +/- 0.9 vs saline: 10.3 +/- 1.4 mL/2 h; P < 0.05), acute furosemide treatment (0.5 +/- 0.2 vs saline: 2.3 +/- 0.6 mL/15 min; P < 0.05), and icv angiotensin II (2.2 +/- 0.8 vs saline: 10.4 +/- 2.0 mL/2 h; P < 0.05), without changing icv carbachol-induced water intake, sodium depletion-induced 1.8% NaCl intake and food deprivation-induced food intake. These data suggest that central ATP, acting on purinergic P2 receptors, reduces water intake induced by intracellular and extracellular dehydration. FAU - de Faria, D R G AU - de Faria DR AD - Departamento de Fisiologia e Patologia, Faculdade de Odontologia de Araraquara, Universidade Estadual Paulista, Araraquara, SP, Brazil. FAU - Santana, J S AU - Santana JS FAU - Menani, J V AU - Menani JV FAU - de Paula, P M AU - de Paula PM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Brazil TA - Braz J Med Biol Res JT - Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas JID - 8112917 RN - 0 (Purinergic P1 Receptor Agonists) RN - 0 (Purinergic P1 Receptor Antagonists) RN - 0 (Purinergic P2 Receptor Agonists) RN - 0 (Purinergic P2 Receptor Antagonists) RN - 0 (Xanthines) RN - 149017-66-3 (pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid) RN - 5V5IOJ8338 (Pyridoxal Phosphate) RN - 8L70Q75FXE (Adenosine Triphosphate) RN - 9PTP4FOI9E (1,3-dipropyl-8-cyclopentylxanthine) SB - IM MH - Adenosine Triphosphate/*administration & dosage/pharmacology MH - Animals MH - Drinking/*drug effects/physiology MH - Eating/drug effects/physiology MH - Injections, Intraventricular MH - Male MH - Purinergic P1 Receptor Agonists MH - Purinergic P1 Receptor Antagonists MH - Purinergic P2 Receptor Agonists MH - Purinergic P2 Receptor Antagonists MH - Pyridoxal Phosphate/administration & dosage/*analogs & derivatives/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Water Deprivation/*physiology MH - Xanthines/*administration & dosage/pharmacology EDAT- 2009/02/17 09:00 MHDA- 2009/10/09 06:00 CRDT- 2009/02/17 09:00 PHST- 2008/09/13 00:00 [received] PHST- 2009/01/20 00:00 [accepted] PHST- 2009/02/17 09:00 [entrez] PHST- 2009/02/17 09:00 [pubmed] PHST- 2009/10/09 06:00 [medline] AID - S0100-879X2009000100015 [pii] AID - 10.1590/s0100-879x2009000100015 [doi] PST - ppublish SO - Braz J Med Biol Res. 2009 Jan;42(1):105-13. doi: 10.1590/s0100-879x2009000100015.